サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1786980

レッドバイオテクノロジーの世界市場、規模、シェア、動向、産業分析レポート：製品別、最終用途別、地域別 - 市場予測（2025年～2034年）

Red Biotechnology Market Size, Share, Trends, Industry Analysis Report By Product (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products), By End Use, By Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 129 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
レッドバイオテクノロジーの世界市場、規模、シェア、動向、産業分析レポート：製品別、最終用途別、地域別 - 市場予測（2025年～2034年）
出版日: 2025年07月01日
発行: Polaris Market Research
ページ情報: 英文 129 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Researchの最新調査によると、世界のレッドバイオテクノロジーの市場規模は、2034年までに1兆4,157億7,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

バイオテクノロジーの一分野であるレッドバイオテクノロジーは、人間の健康増進を目的とした医療・医薬品への応用に焦点を当てています。生体、細胞、生物学的プロセスを利用して、治療法、診断法、病気の予防法を開発します。この分野は、複雑な健康課題に対する革新的な解決策を提供し、現代医学の進歩に重要な役割を果たしています。

レッドバイオテクノロジーの主な用途の1つは、医薬品の開発です。研究者たちは、遺伝子工学を活用して、インスリン、ワクチン、モノクローナル抗体などのバイオ医薬品を製造しています。遺伝子組換えDNA技術により、遺伝子組換え細菌を用いたヒト・インスリンの生産が可能になりました。同様に、COVID-19用に開発されたようなmRNAワクチンや治療薬は、レッドバイオテクノロジーがパンデミックへの迅速な対応を可能にすることを示しています。

レッドバイオテクノロジーは診断ツールや診断技術も強化します。ポリメラーゼ連鎖反応（PCR）や次世代シークエンシング（NGS）などの高度な技術は、がんや感染症などの疾患の早期かつ正確な検出を可能にします。さらにレッドバイオテクノロジーは、B型肝炎、HPV、インフルエンザなどの病気を予防するワクチン開発をサポートしています。合成生物学はワクチン設計を加速し、バイオリアクターは大量生産を容易にします。がん治療では、レッドバイオテクノロジーの革新技術である免疫療法が免疫系を利用して腫瘍を狙い撃ちし、CAR-T細胞などの治療法が特定の血液がんで目覚ましい成功を収めています。

レッドバイオテクノロジー市場レポートのハイライト

製品別では、がん、自己免疫疾患、感染症の治療に広く採用されているモノクローナル抗体が、2024年の市場売上シェアの49.13%を占めました。

最終用途別では、製薬・バイオテクノロジー企業が、生物製剤や先端療法の技術革新、臨床開発、商業化を推進する役割を担っているため、2024年に大きな収益シェアを占めました。

北米は、2024年に世界のレッドバイオテクノロジー市場の34.16％のシェアを占めました。この優位性は、確立されたヘルスケアインフラ、高い研究開発投資、がん、糖尿病、心血管障害などの慢性疾患の有病率の増加に起因しています。

欧州市場は、国民皆保険制度、強力な政府とEUの資金援助、再生医療とバイオシミラーへの注力により、2034年までにかなりのシェアを占めると予測されます。

アジア太平洋市場は、ヘルスケア支出の増加、中間層の増加、感染症および非感染性疾患の高い負担により、2025年～2034年にCAGR15.34%を記録すると予測されます。

レッドバイオテクノロジー市場における世界の主要企業には、アムジェン、アストラゼネカ、バイオジェン、ブリストル・マイヤーズスクイブ、F.ホフマン・ラ・ロシュ、ギリアド・サイエンシズ、メルクKGaA、マブリックス・バイオ、ファイザー、リジェネロン、武田薬品工業などがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のレッドバイオテクノロジー市場の洞察

  • 市場スナップショット
  • レッドバイオテクノロジー市場力学
    • 促進要因と機会
      • 個別化医療の需要増加
      • がん研究への投資拡大
    • 抑制要因と課題
      • 高コスト
  • PESTEL分析
  • レッドバイオテクノロジー市場の動向
  • バリューチェーン分析

第5章 世界のレッドバイオテクノロジー市場：製品別

  • 主な調査結果
  • イントロダクション
  • モノクローナル抗体
  • ポリクローナル抗体
  • 組み換えタンパク質
  • ワクチン
  • 細胞ベースの免疫療法製品
  • 遺伝子治療製品
  • 細胞治療製品
  • 組織工学製品
  • 幹細胞
  • 細胞培養
  • ウイルスベクター
  • 酵素
  • キットと試薬
  • 動物モデル
  • 分子診断
  • その他

第6章 世界のレッドバイオテクノロジー市場：最終用途別

  • 主な調査結果
  • イントロダクション
  • 学術研究機関
  • CMOとCRO
  • 製薬・バイオテクノロジー企業
  • その他

第7章 世界のレッドバイオテクノロジー市場：地域別

  • 主な調査結果
  • イントロダクション
    • レッドバイオテクノロジー市場の評価：地域別、2020～2034年
  • 北米
    • 北米：製品別、2020～2034年
    • 北米：最終用途別、2020～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：製品別、2020～2034年
    • 欧州：最終用途別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋：製品別、2020～2034年
    • アジア太平洋：最終用途別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ
    • 中東・アフリカ：製品別、2020～2034年
    • 中東・アフリカ：最終用途別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：製品別、2020～2034年
    • ラテンアメリカ：最終用途別、2020～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 事業拡大・買収分析
    • 事業拡大
    • 買収
  • 提携/協業/協定/公開

第9章 企業プロファイル

  • AstraZeneca
  • Amgen Inc.
  • Merck & Co
  • Bristol-Myers Squibb
  • Pfizer
  • Biogen
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • MavriX Bio
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company
図表

List of Tables:

  • Table 1 Global Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 2 Global Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 3 North America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 4 North America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 5 U.S.: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 6 U.S.: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 7 Canada: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 8 Canada: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 9 Europe: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 10 Europe: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 11 UK: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 12 UK: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 13 France: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 14 France: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 15 Germany: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 16 Germany: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 17 Italy: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 18 Italy: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 19 Spain: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 20 Spain: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 21 Netherlands: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 22 Netherlands: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 23 Russia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 24 Russia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 25 Rest of Europe: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 26 Rest of Europe: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 27 Asia Pacific: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 28 Asia Pacific: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 29 China: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 30 China: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 31 India: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 32 India: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 33 Malaysia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 34 Malaysia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 35 Japan: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 36 Japan: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 37 Indonesia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 38 Indonesia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 39 South Korea: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 40 South Korea: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 41 Australia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 42 Australia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 43 Rest of Asia Pacific: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 44 Rest of Asia Pacific: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 45 Middle East & Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 46 Middle East & Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 47 Saudi Arabia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 48 Saudi Arabia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 49 UAE: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 50 UAE: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 51 Israel: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 52 Israel: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 53 South Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 54 South Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 55 Rest of Middle East & Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 56 Rest of Middle East & Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 57 Latin America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 58 Latin America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 59 Mexico: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 60 Mexico: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 61 Brazil: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 62 Brazil: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 63 Argentina: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 64 Argentina: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • Table 65 Rest of Latin America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • Table 66 Rest of Latin America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Red Biotechnology Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Product
  • Figure 7. Global Red Biotechnology Market, by Product, 2024 & 2034 (USD Billion)
  • Figure 8. Market by End Use
  • Figure 9. Global Red Biotechnology Market, by End Use, 2024 & 2034 (USD Billion)
目次
Product Code: PM5961

The red biotechnology market size is expected to reach USD 1,415.77 billion by 2034, according to a new study by Polaris Market Research. The report "Red Biotechnology Market Size, Share, Trends, Industry Analysis Report By Product (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products), By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Red biotechnology, a branch of biotechnology, focuses on medical and pharmaceutical applications to improve human health. It involves the use of living organisms, cells, and biological processes to develop therapies, diagnostics, and preventive measures for diseases. This field plays a crucial role in advancing modern medicine, offering innovative solutions for complex health challenges.

One of the primary applications of red biotechnology is in the development of drugs. Researchers produce biopharmaceuticals such as insulin, vaccines, and monoclonal antibodies by leveraging genetic engineering. Recombinant DNA technology enables the production of human insulin using genetically modified bacteria. Similarly, mRNA vaccines and therapeutics, such as those developed for COVID-19, demonstrate how red biotechnology enables rapid responses to pandemics.

Red biotechnology also enhances diagnostic tools and techniques. Advanced techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), enable the early and accurate detection of diseases, including cancers and infectious diseases. Furthermore, red biotechnology supports vaccine development, which prevents diseases such as hepatitis B, HPV, and influenza. Synthetic biology accelerates vaccine design, while bioreactors facilitate large-scale production. In cancer treatment, immunotherapy, a red biotechnology innovation, harnesses the immune system to target tumors, with therapies such as CAR-T cells showing remarkable success in certain blood cancers.

Red Biotechnology Market Report Highlights

In terms of product, the monoclonal antibodies segment accounted for 49.13% of market revenue share in 2024 due to their widespread adoption in the treatment of cancer, autoimmune disorders, and infectious diseases.

Based on end use, the pharmaceutical & biotechnology companies segment accounted for a major revenue share in 2024 due to their role in driving innovation, clinical development, and commercialization of biologics and advanced therapies.

North America accounted for a 34.16% share of the global red biotechnology market in 2024. This dominance is attributed to established healthcare infrastructure, high R&D investments, and a growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders.

The market in Europe is projected to hold a substantial share by 2034 due to universal healthcare systems, strong government and EU funding, and a focus on regenerative medicine and biosimilars.

The market in Asia Pacific is projected to register a CAGR of 15.34% from 2025 to 2034, owing to increasing healthcare spending, a rising middle class, and a high burden of infectious and noncommunicable diseases.

A few global key players in the red biotechnology market include Amgen Inc.; AstraZeneca; Biogen; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck KGaA; MavriX Bio; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

Polaris Market Research has segmented the red biotechnology market report on the basis of product, end use, and region:

By Product Outlook (Revenue, USD Billion, 2020-2034)

Monoclonal Antibodies

Polyclonal Antibodies

Recombinant Proteins

Vaccines

Cell-Based Immunotherapy Products

Gene Therapy Products

Cell Therapy Products

Tissue-Engineered Products

Stem Cells

Cell Culture

Viral Vector

Enzymes

Kits and Reagents

Animal Models

Molecular Diagnostics

Other

By End Use Outlook (Revenue, USD Billion, 2020-2034)

Academic Research Institutes

CMOs & CROs

Pharmaceutical & Biotechnology Companies

Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Red Biotechnology Market Insights

  • 4.1. Red Biotechnology Market - Market Snapshot
  • 4.2. Red Biotechnology Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Demand for Personalized Medicine
      • 4.2.1.2. Rising Investment in Cancer Research
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Red Biotechnology Market Trends
  • 4.6. Value Chain Analysis

5. Global Red Biotechnology Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
  • 5.3. Monoclonal Antibodies
    • 5.3.1. Global Red Biotechnology Market, by Monoclonal Antibodies, by Region, 2020-2034 (USD Billion)
  • 5.4. Polyclonal Antibodies
    • 5.4.1. Global Red Biotechnology Market, by Polyclonal Antibodies, by Region, 2020-2034 (USD Billion)
  • 5.5. Recombinant Proteins
    • 5.5.1. Global Red Biotechnology Market, by Recombinant Proteins, by Region, 2020-2034 (USD Billion)
  • 5.6. Vaccines
    • 5.6.1. Global Red Biotechnology Market, by Vaccines, by Region, 2020-2034 (USD Billion)
  • 5.7. Cell-Based Immunotherapy Products
    • 5.7.1. Global Red Biotechnology Market, by Cell-Based Immunotherapy Products, by Region, 2020-2034 (USD Billion)
  • 5.8. Gene Therapy Products
    • 5.8.1. Global Red Biotechnology Market, by Gene Therapy Products, by Region, 2020-2034 (USD Billion)
  • 5.9. Cell Therapy Products
    • 5.9.1. Global Red Biotechnology Market, by Cell Therapy Products, by Region, 2020-2034 (USD Billion)
  • 5.10. Tissue-Engineered Products
    • 5.10.1. Global Red Biotechnology Market, by Tissue-Engineered Products, by Region, 2020-2034 (USD Billion)
  • 5.11. Stem Cells
    • 5.11.1. Global Red Biotechnology Market, by Stem Cells, by Region, 2020-2034 (USD Billion)
  • 5.12. Cell Culture
    • 5.12.1. Global Red Biotechnology Market, by Cell Culture, by Region, 2020-2034 (USD Billion)
  • 5.13. Viral Vector
    • 5.13.1. Global Red Biotechnology Market, by Viral Vector, by Region, 2020-2034 (USD Billion)
  • 5.14. Enzymes
    • 5.14.1. Global Red Biotechnology Market, by Enzymes, by Region, 2020-2034 (USD Billion)
  • 5.15. Kits and Reagents
    • 5.15.1. Global Red Biotechnology Market, by Kits and Reagents, by Region, 2020-2034 (USD Billion)
  • 5.16. Animal Models
    • 5.16.1. Global Red Biotechnology Market, by Animal Models, by Region, 2020-2034 (USD Billion)
  • 5.17. Molecular Diagnostics
    • 5.17.1. Global Red Biotechnology Market, by Molecular Diagnostics, by Region, 2020-2034 (USD Billion)
  • 5.18. Others
    • 5.18.1. Global Red Biotechnology Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Red Biotechnology Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 6.3. Academic Research Institutes
    • 6.3.1. Global Red Biotechnology Market, by Academic Research Institutes, by Region, 2020-2034 (USD Billion)
  • 6.4. CMOs & CROs
    • 6.4.1. Global Red Biotechnology Market, by CMOs & CROs, by Region, 2020-2034 (USD Billion)
  • 6.5. Pharmaceutical & Biotechnology Companies
    • 6.5.1. Global Red Biotechnology Market, by Pharmaceutical & Biotechnology Companies, by Region, 2020-2034 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Red Biotechnology Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Red Biotechnology Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Red Biotechnology Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 7.3. Red Biotechnology Market - North America
    • 7.3.1. North America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.3.2. North America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.3.3. Red Biotechnology Market - U.S.
      • 7.3.3.1. U.S.: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.3.3.2. U.S.: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.3.4. Red Biotechnology Market - Canada
      • 7.3.4.1. Canada: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.3.4.2. Canada: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.4. Red Biotechnology Market - Europe
    • 7.4.1. Europe: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.4.2. Europe: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.3. Red Biotechnology Market - UK
      • 7.4.3.1. UK: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.4.3.2. UK: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.4. Red Biotechnology Market - France
      • 7.4.4.1. France: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.4.4.2. France: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.5. Red Biotechnology Market - Germany
      • 7.4.5.1. Germany: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.4.5.2. Germany: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.6. Red Biotechnology Market - Italy
      • 7.4.6.1. Italy: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.4.6.2. Italy: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.7. Red Biotechnology Market - Spain
      • 7.4.7.1. Spain: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.4.7.2. Spain: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.8. Red Biotechnology Market - Netherlands
      • 7.4.8.1. Netherlands: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.4.8.2. Netherlands: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.9. Red Biotechnology Market - Russia
      • 7.4.9.1. Russia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.4.9.2. Russia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.10. Red Biotechnology Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.4.10.2. Rest of Europe: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.5. Red Biotechnology Market - Asia Pacific
    • 7.5.1. Asia Pacific: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.5.2. Asia Pacific: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.3. Red Biotechnology Market - China
      • 7.5.3.1. China: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.5.3.2. China: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.4. Red Biotechnology Market - India
      • 7.5.4.1. India: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.5.4.2. India: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.5. Red Biotechnology Market - Malaysia
      • 7.5.5.1. Malaysia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.5.5.2. Malaysia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.6. Red Biotechnology Market - Japan
      • 7.5.6.1. Japan: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.5.6.2. Japan: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.7. Red Biotechnology Market - Indonesia
      • 7.5.7.1. Indonesia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.5.7.2. Indonesia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.8. Red Biotechnology Market - South Korea
      • 7.5.8.1. South Korea: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.5.8.2. South Korea: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.9. Red Biotechnology Market - Australia
      • 7.5.9.1. Australia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.5.9.2. Australia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.10. Red Biotechnology Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.5.10.2. Rest of Asia Pacific: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.6. Red Biotechnology Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.6.2. Middle East & Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.3. Red Biotechnology Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.4. Red Biotechnology Market - UAE
      • 7.6.4.1. UAE: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.6.4.2. UAE: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.5. Red Biotechnology Market - Israel
      • 7.6.5.1. Israel: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.6.5.2. Israel: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.6. Red Biotechnology Market - South Africa
      • 7.6.6.1. South Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.6.6.2. South Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.7. Red Biotechnology Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.6.7.2. Rest of Middle East & Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
  • 7.7. Red Biotechnology Market - Latin America
    • 7.7.1. Latin America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
    • 7.7.2. Latin America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.7.3. Red Biotechnology Market - Mexico
      • 7.7.3.1. Mexico: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.7.3.2. Mexico: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.7.4. Red Biotechnology Market - Brazil
      • 7.7.4.1. Brazil: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.7.4.2. Brazil: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.7.5. Red Biotechnology Market - Argentina
      • 7.7.5.1. Argentina: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.7.5.2. Argentina: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
    • 7.7.6. Red Biotechnology Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
      • 7.7.6.2. Rest of Latin America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AstraZeneca
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Amgen Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Merck & Co
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bristol-Myers Squibb
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Pfizer
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Biogen
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. F. Hoffmann-La Roche Ltd
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Gilead Sciences, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. MavriX Bio
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Regeneron Pharmaceuticals, Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Takeda Pharmaceutical Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development